Boston Scientific Corp stated on Friday it would continue helping patients with irregular heartbeat by expanding its own piles of products. The medical device maker would buy C.R. Bard Inc's electrophysiology (EP) firm for a total of US$275 million which would directly set off its cause.

According to Boston Scientific, Bard's Electrophyisiology market manufactured recording devices and catheters for curative and diagnostic purposes. The EP firm was assessed to be US$2.5 billion internationally and was booming at around 10% yearly.

In 2012, Bard's EP was able to generate US$111 million in sales. Its 180 employees worldwide were all set to join the Rhythm Management business of Boston Scientific.

The said producer of medical devices was expected to settle the agreement within the year. It further presumed that the deal would increase its share by 1% for the next twelve months.

Boston Scientific's president and chief executive officer, Mike Mahoney, said, "We believe the innovation and global reach that Bard EP delivers will meaningfully advance our position in this fast-growing market."